Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

pT1 bladder cancer.

H Herr1, G Jakse

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, N.Y.

European Urology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

pT1 bladder cancer is more aggressive than superficial types. Intravesical therapies like chemotherapy or BCG significantly reduce the risk of muscle invasion after transurethral resection for these bladder tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of Single-Top-Quark Production in Association with a Photon Using the ATLAS Detector.

Physical review letters·2023
Same author

Observation of the γγ→ττ Process in Pb+Pb Collisions and Constraints on the τ-Lepton Anomalous Magnetic Moment with the ATLAS Detector.

Physical review letters·2023
Same author

Strong Constraints on Jet Quenching in Centrality-Dependent p+Pb Collisions at 5.02 TeV from ATLAS.

Physical review letters·2023
Same author

Search for Heavy Neutral Leptons in Decays of W Bosons Using a Dilepton Displaced Vertex in sqrt[s]=13  TeV pp Collisions with the ATLAS Detector.

Physical review letters·2023
Same author

First evidence for fin whale migration into the Pacific from Antarctic feeding grounds at Elephant Island.

Royal Society open science·2022
Same author

Observation of WWW Production in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2022

Area of Science:

  • Uro-oncology
  • Cancer research
  • Clinical urology

Background:

  • pT1 bladder tumors invade the lamina propria, exhibiting greater biological aggressiveness than superficial pTa or carcinoma in situ (Tis).
  • Transurethral resection (TUR) is a primary treatment for pT1 bladder cancer, but a significant percentage of patients experience disease progression.

Purpose of the Study:

  • To evaluate the efficacy of intravesical therapies in reducing muscle-invasive progression of pT1 bladder tumors post-TUR.
  • To identify key tumor characteristics associated with an increased risk of progression.

Main Methods:

  • Retrospective analysis of patients with pT1 bladder tumors treated with TUR.
  • Comparison of progression rates between patients receiving intravesical chemotherapy or Bacillus Calmette-Guérin (BCG) versus those without adjuvant therapy.

Related Experiment Videos

  • Identification of prognostic factors for muscle-invasive progression.

    • Main Results:

    • Without intravesical therapy, 30% of pT1 tumors progressed to muscle-invasive disease within 3-5 years.
    • Intravesical chemotherapy reduced progression rates to 20%, while BCG reduced them to 14%.
    • Factors predicting progression included multiple/recurrent pT1 tumors, high grade (G3), solid configuration, and associated Tis.

    Conclusions:

    • Intravesical chemotherapy and BCG are effective in reducing the risk of muscle-invasive progression in pT1 bladder cancer following TUR.
    • Conservative management is feasible for many pT1 tumors, but cystectomy should be considered for patients refractory to TUR and intravesical therapy.